Cancer Biology

822 A precision therapy against cancers driven by KIT/PDGFRA mutations.

821 Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients.

820 Metabolic flux analysis in mice reveals that lactate often acts as the primary carbon source for the tricarboxylic acid cycle both in normal tissues and in tumour microenvironments.

819 Association analysis identifies 65 new breast cancer risk loci, predicts target genes for known risk loci and demonstrates a strong overlap with somatic driver genes in breast tumours.

818 Breast tumor cell-specific knockout of Twist1 inhibits cancer cell plasticity, dissemination, and lung metastasis in mice.

817 Neural signals promote prostate cancer growth by altering endothelial cell metabolism and inducing tumor angiogenesis.

816 Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia.

815 Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

814 Fructose-1,6-bisphosphate couples glycolytic flux to activation of Ras.

813 Detection of dysregulated protein-association networks by high-throughput proteomics predicts cancer vulnerabilities.

812 Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells.

811 Use of CRISPR-modified human stem cell organoids to study the origin of mutational signatures in cancer.

810 An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors.

809 Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.

808 Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts.

807 Analysis of global remethylation in mouse embryos at several developmental stages identifies an epigenetic landscape that partitions extraembryonic tissues within the embryo and resembles a frequent, global departure in genome regulation in human cancers.

806 Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism.

805 Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen–specific CTLs.

804 Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.

803 Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma.

Free Images for Presentation: sunipix SUNIPIX